Request Demo

Last update 08 May 2025

Cayler Cardiofacial Syndrome

Last update 08 May 2025

Basic Info

Synonyms

ACF, ASYMMETRIC CRYING FACIES, Asymmetric crying face

+ [36]

Introduction

A rare, isolated, congenital, head and neck morphological anomaly characterized by the unilateral hypoplasia/agenesis of the depressor anguli oris muscle, resulting in an asymmetric crying facies in neonatal period/infancy (drooping of one corner of the mouth during crying) while eye closure, nasolabial fold and forehead wrinkling are symmetric. Although isolated in the majority of cases, newborns presenting with this morphological anomaly should be referred for further screening for 22q11.2 deletion syndrome and/or other coexisting cardiovascular, musculoskeletal, cervicofacial, respiratory, genitourinary and endocrine anomalies.

Clinical Trials associated with Cayler Cardiofacial Syndrome

NCT04934176

/ RecruitingNot ApplicableIIT

3D Dynamic and Patient-Centered Outcomes of Facial Reanimation

In this study, patients who have undergone facial paralysis surgery will be asked to participate. The goal of this study is to compare the facial disability and perception outcomes of facial reanimation surgeries in patients with extensive and permanent, unilateral paralysis using 3D analysis, and compare patient-centered outcomes of facial appearance, well-being, and satisfaction using validated questionnaires. The focus point of this study will be on outcomes of mid-facial reanimation surgeries in patients with more extensive and permanent, unilateral, paralysis of varied etiology and presentation.
The specific aims of the study are as follows. Specific Aim 1. To quantitatively determine the surgical effects/impact on facial disability (facial impairment and disfigurement) among four surgically treated groups of patients with unilateral facial paralysis who undergo free gracilis muscle transfer driven by (1) a trigeminal nerve (nV) graft, (2) a crossface nerve graft (nVII), (3) dual innervation comprising both nerves, and (4) midfacial modification.
1. We will compare the changes in facial disability among the groups before and after surgery, and the differences in facial disability between each surgery group and the controls before and after surgery.
2. Specific Aim 2. To compare among the surgery groups the changes in self-perceptions of facial appearance and well-being that occur due to facial reanimation surgery, and to compare the surgery groups before and at 18 months to historical controls recruited during the tenure of the R21 grant.
3. Specific Aim 3. In patients with facial paralysis, to compare surgeons' current qualitative assessment and 2D, quantitative assessment of facial impairment and disfigurement with the objective, 3D, quantitative assessments in order to determine the clinical utility of the 3D assessment approach as an outcome measure and relevance for dissemination to the surgical community.

Start Date03 Jun 2021

Sponsor / Collaborator

Tufts University

[+2]

NCT04543318

/ Unknown statusNot ApplicableIIT

Using the Deep Temporal Nerves Versus the Masseteric Nerve for Correction of Eyelid Paresis Caused by Facial Nerve Affection. A Comparative Clinical Study.

The return of eyelid function and facial expression in Patients with facial nerve affection is very important for quality of life. Eyelid dysfunction leads to drying and ulceration of cornea which may lead to permanent vision loss.
Facial paralysis is distinguished into two main groups according to the presence or absence of facial fibrillations at needle Electromyography. Recent paralysis, mainly lasting less than two years generally show these signs and are eligible for reactivation of facial nerve by anastomosing it to a donor one (early facial reanimation).
The masseteric nerve (motor branch of trigeminal nerve ) is a reliable donor nerve on early facial reanimation.
The deep temporal nerves are motor branches of trigeminal nerve which have some advantage over masseteric nerve as they are longer and reach the zygomatic and frontal branch of facial nerve and it can reach the eyelid and eyebrow to be used for direct neurotization and it supplies temporalis muscle which is an expandable muscle with little effect on mastication and it was reported that they can restore blinking.
So on this study we examine the advantages and disadvantages of both nerves to develop a protocol for use of both especially on eyelid reanimation and restoration of blinking on upper facial segment paresis

Start Date01 Nov 2020

Sponsor / Collaborator

Assiut University

JPRN-jRCTs031180094

/ CompletedPhase 2IIT

The efficacy of Leukotriene receptor antagonist for human rectal aberrant crypt foci: nonrandomized open label controlled trial

Start Date15 Dec 2017

Sponsor / Collaborator-

100 Clinical Results associated with Cayler Cardiofacial Syndrome

100 Translational Medicine associated with Cayler Cardiofacial Syndrome

0 Patents (Medical) associated with Cayler Cardiofacial Syndrome

340

Literatures (Medical) associated with Cayler Cardiofacial Syndrome

01 May 2025·Neurosurgery

Microsurgical Treatment of Intracranial Dural Arteriovenous Fistulas: A Collaborative Investigation From the Multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research

Article

Author: Samaniego, Edgar A. ; Gross, Bradley A. ; Amin-Hanjani, Sepideh ; Levitt, Michael R. ; Durnford, Andrew J. ; Abla, Adib A. ; Tada, Yoshiteru ; Tonetti, Daniel A. ; Lai, Pui Man Rosalind ; Satomi, Junichiro ; Kansagra, Akash P. ; Abecassis, Isaac Josh ; Guniganti, Ridhima ; Polifka, Adam J. ; Chen, Stephanie ; Derdeyn, Colin P. ; Brinjikji, Waleed ; Giordan, Enrico ; Abdelsalam, Ahmed ; Hayakawa, Minako ; Potgieser, Adriaan R. E. ; Du, Rose ; Alaraj, Ali ; Eatz, Tiffany ; Raper, Daniel M. S. ; Bulters, Diederik O. ; Zipfel, Gregory J. ; Lanzino, Giuseppe ; Peterson, Eric C. ; Sheehan, Jason ; Kwasnicki, Amanda ; Raygor, Kunal P. ; Starke, Robert M. ; van Dijk, J. Marc C. ; Fox, W. Christopher ; Chen, Ching-Jen ; Kim, Louis

BACKGROUND AND OBJECTIVES:First-line therapy for most intracranial dural arteriovenous fistulas (dAVFs) is endovascular embolization, but some require microsurgical ligation due to limited endovascular accessibility, anticipated lower cure rates, or unacceptable risk profiles. We investigated the most common surgically treated dAVF locations and the approaches and outcomes of each.METHODS:The Consortium for Dural Arteriovenous Fistula Outcomes Research database was retrospectively reviewed. Patients who underwent dAVF microsurgical ligation were included. Patient demographics, angiographic information, surgical details, and postoperative outcomes were collected. The 5 most common surgically treated dAVF locations were analyzed about used surgical approaches and postoperative outcomes. Univariate analyses were performed with statistical significance set at a threshold of P < .05.RESULTS:In total, 248 patients in the Consortium for Dural Arteriovenous Fistula Outcomes Research database met inclusion criteria. The 5 most common surgically treated dAVF locations were tentorial, anterior cranial fossa (ACF), transverse-sigmoid sinus (TSS), convexity/superior sagittal sinus (SSS), and torcular. Most tentorial dAVFs were approached using a suboccipital, lateral supracerebellar infratentorial approach (39.3%); extended retrosigmoid approach (ERS) (25%); or posterior subtemporal approach (19.6%). All ACF dAVFs used a subfrontal approach; 5.3% also included an anterior interhemispheric approach. Most TSS dAVFs were ligated via ERS (31.3%) or subtemporal (31.3%) approaches. All convexity/SSS dAVFs used an interhemispheric approach. All torcular dAVFs used the suboccipital, lateral supracerebellar infratentorial approach, with 10.5% undergoing simultaneous ERS craniotomy. Angiographic occlusion rates after microsurgery were 85.5%, 100%, 75.8%, 79.2%, and 73.7% for tentorial, ACF, TSS, convexity/SSS, and torcular dAVFs, respectively (P = .02); the permanent neurological complication rates were 1.8%, 2.6%, 9.1%, 0%, and 0% (P = .31). There were no statistically significant differences in development of complications (P = .08) or Modified Rankin Scale at the last follow-up (P = .11) by fistula location.CONCLUSION:Although endovascular embolization is the first-line treatment for most intracranial dAVFs, surgical ligation is an important alternative. ACF and tentorial fistulas particularly demonstrate high rates of postoperative obliteration.

01 Apr 2025·International Journal of Surgery Case Reports

Coexistence of three dural arteriovenous fistulas in the anterior cranial fossa, petrous ridge and superior sagittal sinus: A case report

Article

Author: Xie, Xinyu ; Xu, Kan ; Yu, Jinlu ; Wang, Shutao

INTRODUCTION AND IMPORTANCEThe coexistence of three dural arteriovenous fistulas (DAVFs) in the anterior cranial fossa (ACF), petrous ridge and superior sagittal sinus (SSS) is rare. Such a complex and rare case can be managed with endovascular treatment (EVT).CASE PRESENTATIONA 74-year-old male with an intracranial hemorrhage was admitted in a comatose state. His Hunt-Hess scale - was grade III. Computed tomography (CT) revealed frontal lobe hemorrhage into lateral ventricle. Digital subtraction angiography (DSA) revealed the coexistence of three DAVFs in the ACF, left petrous ridge and right SSS. The ruptured DAVF in the ACF was embolized via the ophthalmic artery with the assistance of the "pressure cooker" technique. Then, the DAVF in the petrous ridge was embolized via the middle meningeal artery. The DAVF in the SSS was not managed due to low Cognard classification. Burr hole drainage of the frontal lobe hematoma and intraventricular hemorrhage was performed immediately after EVT. The patient gradually recovered after treatment. At the 2-week follow-up, the patient could answer simple questions, and his upper and lower limbs had grade V muscle strength. CT revealed that the intracranial hemorrhage had been absorbed. During the 3-month follow-up, the patient reported that he could take care of himself.CLINICAL DISCUSSIONWhen ACF DAVF was involved in multiple DAVFs, it was often symptomatic and ruptured. Burr hole drainage may be necessary when intracranial hemorrhage was serious.CONCLUSIONIn multiple DAVF, those with high Cognard classification should receive aggressive treatment. EVT may be an option.

01 Mar 2025·Aesthetic Plastic Surgery

Evaluation of Facial Symmetry in Congenital Unilateral Lower Lip Palsy Patients with Depressor Labii Inferioris Muscle Resection

Article

Author: Zhou, Yang ; Qu, Siwei ; Ji, Kai ; Chen, Jian ; Shen, Sile ; Wang, Chengyuan

BACKGROUNDCongenital hypoplasia of the depressor labii inferioris muscle can lead to Asymmetrical crying facies(ACF). The objective of this research was to examine the alterations in both static and dynamic facial symmetry following the resection of the depressor labii inferioris on the healthy side through an intraoral approach.METHODSPatients exhibiting palsy of the depressor labii inferioris muscles were included in the study. smile modiolus angle, excursion, and exposure of teeth were assessed on both sides before and after resection of the depressor labii inferioris using Emotrics photographic analysis.RESULTSThirty-six patients were included. Before the resection of the depressor labii inferioris, the modiolus excursion of the closed-mouth smile is significantly asymmetric (p = 0.001), and after the operation, it becomes symmetric (p= 0.185). The change of symmetry with modiolus angle and teeth exposure in an open-mouth smile are the most significant. The surgery can turn the obvious skew lip (p<0.0001) into an almost symmetrical (modiolus angle: p = 0.321; teeth exposure: p = 0.368) expression. The teeth exposure significantly reduced on the healthy side (p<0.01).CONCLUSIONSACF patients have asymmetry both in closed-mouth and open-mouth smiles. Resection of the depressor labii inferioris muscle offers a treatment that rapidly improves the symmetry of closed-mouth and open-mouth smiles.LEVEL OF EVIDENCE IIThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

News (Medical) associated with Cayler Cardiofacial Syndrome

01 Jul 2022

·www.prnewswire.com

Sanofi flu vaccines licensed and approved for 2022-2023 influenza season, including CDC preferred higher-dose vaccines for adults 65+

* Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine) are the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators as assessed in randomized controlled trials, the gold standard in evaluating clinical evidence for vaccine licensure1,2 * Fluzone® High-Dose (Influenza Vaccine) is the first and only influenza vaccine with superior flu protection and 10 years of evidence in preventing flu-related hospitalizations in adults aged 65+2,3,a,b * As the leaders in flu, Sanofi is committed to protecting patients most at-risk for the flu and its related complications, including hospitalizations due to pneumonia & cardiovascular events4 BRIDGEWATER, N.J., July 1, 2022 /PRNewswire/ -- Today the US Food and Drug Administration (FDA) approved Sanofi's licensure request for vaccine approval for the upcoming 2022-2023 flu season, including: Fluzone High-Dose Quadrivalent (Influenza Vaccine), Flublok Quadrivalent (Influenza Vaccine) and Fluzone Quadrivalent (Influenza Vaccine).5 This approval comes on the heels of the CDC's Advisory Committee on Immunization Practices (ACIP) preferential recommendation for adults 65+ including Fluzone High-Dose Quadrivalent and Flublok Quadrivalent.6 Following this licensure, Sanofi will begin to ship their vaccines helping to ensure more people, including some of our most vulnerable population of 65 years and older, will be immunized with the vaccine best suited for their needs as recommended by the ACIP. Influenza disproportionately impacts people over 65, underrepresented communities, and people with co-morbidities such as diabetes, asthma, chronic obstructive pulmonary disease, and heart disease.7 Since 2010, it's estimated by the CDC that between 70% and 85% of seasonal flu-related deaths have occurred in people 65+, and between 50% and 70% of seasonal flu-related hospitalizations have occurred among people in this age group.4 ACIP's June 22nd recommendation will undoubtedly help reduce the risk of influenza cases and severe flu-related complications in this population at highest risk. Michael Greenberg, MD, MPH North America Medial Head of Vaccines at Sanofi "ACIP's recommendation is a first step to help improve protection against flu and its complications for this 65 years and older high-risk population. Not every flu vaccine is created equal and we are pleased with ACIP's acknowledgment that Fluzone High-Dose Quadrivalent & Flublok Quadrivalent have demonstrated improved protection from flu & its related complications through randomized controlled trials and real-world evidence.8 Of note ACIP recognized that Fluzone High-Dose Quadrivalent had the most data available, including evidence favoring its use over standard dose for all the benefit outcomes within the GRADE analysis; influenza illnesses, outpatient/ER visits, hospitalizations, and deaths.8 Nevertheless, we believe even more can be done to provide healthcare providers with clearer guidance. As a leader in flu vaccination, we remain committed to ensure adults 65 years and older have access to flu vaccines, proven to protect them from what really matters, such as flu-related hospitalizations due to cardiovascular events and pneumonia." About the Composition of Sanofi's 2022-2023 Licensed and Approved Influenza Vaccines Each year, the FDA, World Health Organization (WHO), Centers for Disease Control and Prevention, and other partners collaborate by collecting and reviewing data on the circulating strains of influenza from around the world to identify those likely to cause the most illness in the upcoming flu season.9 Once strains are selected, flu vaccine manufacturers include the newly selected flu strains in their FDA-approved vaccines, and then submit applications to the FDA to include the new flu strains in their FDA-approved vaccines, including for Fluzone High-Dose Quadrivalent, Flublok Quadrivalent and Fluzone Quadrivalent.9 Today those requests for licensure were approved for the upcoming 2022-2023 flu season.5 About Fluzone® Quadrivalent (Influenza Vaccine), Flublok® Quadrivalent (Influenza Vaccine) and Fluzone® High-Dose Quadrivalent (Influenza Vaccine) Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are vaccines indicated for immunization against disease caused by influenza A and B strains contained in the vaccine. Fluzone Quadrivalent is given to people 6 months of age and older. Flublok Quadrivalent is given to people 18 years of age and older. Fluzone High-Dose Quadrivalent is given to people 65 years of age and older. With protection against four flu strains, Fluzone High-Dose is the only influenza vaccine licensed for use in adults 65 years of age and older to have demonstrated superior efficacy in a randomized controlled trial versus a standard dose influenza vaccine for the prevention of laboratory-confirmed influenza illness and the only influenza vaccine with 10 years of data demonstrating protection from flu and its related complications.2,3,a,b In a meta-analysis of 15 published reports, including approximately 34 million people, those who received Fluzone High-Dose experienced an 18% reduction in cardiorespiratory hospitalizations and 28% decrease in pneumonia hospitalizations, both of which are reductions above what the standard dose vaccines provided.3 Fluzone High-Dose Quadrivalent builds on the legacy of the trivalent formulation, which was clinically proven to be 24.2% more effective at preventing flu than standard-dose Fluzone (Influenza Vaccine) in adults 65+.10 Based on data from Fluzone High-Dose (Influenza Vaccine), side effects were slightly more frequent after vaccination with Fluzone High-Dose compared to a standard-dose vaccine.11 The efficacy of trivalent formulation is relevant to Fluzone High-Dose Quadrivalent since both products are manufactured according to the same process and have overlapping compositions.2 In a clinical study, Flublok Quadrivalent is the first and only recombinant influenza vaccine for adults 18+ that was proven to be 30% more effective than a standard dose vaccine at preventing flu infection in over 9,000 adults 50+.1 In adults 50+, the most common side effects were tenderness, and/or pain at the injection site; headache, and tiredness.1 aProven superiority in a clinical trial between Fluzone High-Dose (Influenza Vaccine) (trivalent formulation) and a standard-dose influenza vaccine2 bIncludes 10 years of evidence (2009-2019) with Fluzone High-Dose (trivalent formulation)3 Important Safety Information for Fluzone® Quadrivalent (Influenza Vaccine), Flublok® Quadrivalent (Influenza Vaccine) and Fluzone® High-Dose Quadrivalent (Influenza Vaccine) Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be given to anyone who has had a severe allergic reaction to any component of the vaccine (including eggs or egg products for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after previous dose of the vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be given to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine. Tell your health care provider if you have ever had Guillain-Barré syndrome (severe muscle weakness) after a previous influenza vaccination. If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are given to people with a compromised immune system, including those receiving therapies that suppress the immune system, the immune response may be lower than expected. Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all people who receive the vaccine. For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common side effects were pain, tenderness, redness, and/or swelling where you got the shot; irritability, abnormal crying, general discomfort, drowsiness, loss of appetite, muscle aches, vomiting, and fever. In children 3 years through 8 years of age, the most common side effects were pain, redness, and/or swelling where you got the shot; muscle aches, general discomfort, and headache. In adults 18 years and older, the most common side effects were pain where you got the shot; muscle aches, headache, and general discomfort. For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common side effects were tenderness, and/or pain where you got the shot; headache, tiredness, muscle aches, and joint pain. In adults 50 years of age and older the most common side effects were tenderness, and/or pain where you got the shot; headache and tiredness. For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common side effects were pain, redness, and/or swelling where you got the shot; muscle aches, headache, and general discomfort. For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other side effects may occur. Please refer to the full Prescribing Information for Fluzone High-Dose Quadrivalent, Flublok Quadrivalent, or Fluzone Quadrivalent. Also please see complete Patient Information for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent.  About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY Media Relations Evan Berland | + 1 215 432 0234 | [email protected] Sally Bain | + 1 781 264 1091 | [email protected] Kate Conway | + 1 617 981 2738 | [email protected] Investor Relations Eva Schaefer-Jansen | + 33 7 86 80 56 39 | [email protected] Arnaud Delépine | + 33 6 73 69 36 93 | [email protected] Corentine Driancourt | + 33 6 40 56 92 21 | [email protected] Felix Lauscher | + 1 908 612 7239 | [email protected] Priya Nanduri | +1 617 764 6418| [email protected]   Nathalie Pham | + 33 7 85 93 30 17 | [email protected] Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. References 1Flublok Quadrivalent [Prescribing Information]. Swiftwater, PA: Sanofi 2Fluzone High-Dose Quadrivalent [Prescribing Information]. Swiftwater, PA: Sanofi 3Lee JKH, Lam GKL, Shin T, et al. (2021) Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: An updated systematic review and meta-analysis. Vaccine 2021; 39: A24-A35. . 4Centers for Disease Control and Prevention. Flu & People 65 Years and Older. Available at: . Accessed June 2022. 5FDA Approval of Sanofi Licensure Request for Vaccine Approval for 2022-2023 Influenza Season [Data on File] 6Centers for Disease Control and Prevention. ACIP Flu Meeting Update: Flu Vaccines Worked Better than Reported & ACIP Recommends Specific Vaccines for Seniors. Available at . Accessed June 2022. 7Centers for Disease Control and Prevention. People at Higher Risk for Flu Complications. Available at: . Accessed June 2022. 8Grohskoph L. Influenza Vaccines for Persons Aged ≥65 Years: Evidence to Recommendations (EtR) Framework. Available at . Accessed on June 22, 2022. 9Centers for Disease Control and Prevention. Selecting Viruses for the Seasonal Influenza Vaccine. Available at . Accessed June 2022. 10DiazGranados CA, et al. N Engl J Med. 2014;371(7):635-645 11Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):172-180. doi:10.1086/599790 SOURCE Sanofi

VaccineFinancial StatementCollaborate

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cayler Cardiofacial Syndrome

Basic Info

Related

Analysis